Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dominog effect: drugs with an uncertain pricing future in Germany

This article was originally published in Scrip

Executive Summary

News that gliptins already on the market are to undergo the early benefit assessment in Germany should be sounding warning bells for dozens of recently approved drugs in Germany – and for their competitors. Retrospective action could mean not only lower prices, but potentially the strategic withdrawal of drugs from the German market so that prices in Germany do not erode prices elsewhere in Europe, say industry commentators.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC017774

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel